Lillie James Woodruff
Known title: Chief Scientific OfficerCIK: 0001728746
Associated companies
Transaction History
| MPLT | ▲ Buy | Grant | 7,730 | $0 | 8/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 22,082 | $277K | 8/3/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,077 | $79K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 12 | $456 | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,009 | $183K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,526 | $131K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,238 | $81K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,393 | $199K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 12 | $450 | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 721 | $20K | 5/7/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 8,390 | $235K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 16,421 | $478K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 10,132 | $285K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 963 | $28K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,250 | $254K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,526 | $157K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 320 | $9K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 705 | $21K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 686 | $19K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,097 | $58K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1,730 | $46K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 7,730 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 45,055 | $810K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 32,539 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.